CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

Planning Enters Next Hhase as ABMS Announces Open Comment Period

Efforts by the American College of Cardiology, the American Heart Association, the Heart Failure Society of America, the Heart Rhythm Society and The Society for Cardiovascular Angiography & Interventions to create a new, independent Board of Cardiovascular Medicine under the American Board of Medical Specialties (ABMS) are closer to becoming a reality with the creation of a formal Board of Directors and the announcement by the ABMS Advisory Board on Specialty Board Development of an open comment period.

The 90-day open comment period announced by ABMS on April 24 is a critical part of the application review process and a vital cornerstone for engagement in the decision-making process. Running through July 24, ABMS is seeking to gauge support for the new Board, including feedback on its impact to clinicians and patients.

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

A diverse range of stakeholders, including cardiologists, other health care professionals, cardiovascular patients, cardiovascular organizations, and the public are invited to share their perspectives on the new Board, including whether it meets the ABMS requirements for both initial certification and continuing competency. Comments can be submitted via the ABMS website.

In addition to the comment period, the first 10 directors of the prospective Board have been selected, with an additional five directors soon to be named. As leaders in their respective fields, the Board of Directors will be instrumental in ushering the new Board through the application process and overseeing pre-launch projects in anticipation of Board approval.

The initial Directors include:

  • Mark H. Drazner, MD (Treasurer)
  • Peter L. Duffy, MD
  • David P. Faxon, MD
  • Edward T. A. Fry, MD
  • Judith S. Hochman, MD
  • Jodie L. Hurwitz, MD (Secretary)
  • Michelle Maya Kittleson, MD
  • Daniel M. Kolansky, MD
  • Jeffrey T. Kuvin, MD (President)
  • Gregory F. Michaud, MD

“Cardiologists have a responsibility to maintain clinical competency to ensure patients receive the best possible care. To facilitate career-long learning, a new model of certification tailored to the unique needs of cardiology is needed,” the Directors said in a joint statement. “An independent Board focused solely on cardiovascular medicine as a distinct medical specialty will ultimately benefit cardiologists and patients alike.”

The Directors’ initial work will establish the framework needed to pave the way for a successful launch of the proposed Board of Cardiovascular Medicine, which includes crafting clear bylaws that outline the Board’s structure and decision-making processes, establishing vital committees to manage specific Board processes and subspecialties, developing a sound budget, managing financial processes, and defining a tailored continuous competency certification process.

About the Proposed Board of Cardiovascular Medicine

For over 80 years, cardiovascular medicine has been incorporated under the American Board of Internal Medicine (ABIM). However, given decades of advancements in the field, cardiologists across the country have come together to move towards a new Board that recognizes cardiovascular medicine as a medical specialty distinct from internal medicine. The proposed independent Board of Cardiovascular Medicine, governed by cardiologists for cardiologists, would facilitate a deep understanding of competencies to ensure high-value cardiovascular patient care. The underpinnings of true lifelong learning and practical skills development proposed by the new Board will support clinicians in achieving and maintaining clinical competency. For more information, visit: https://CVBoard.org.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”